Article | October 11, 2022

Start With ‘Why' When Adopting New Tech To Support Hybrid Decentralized Trials

Source: Medrio

By Nicole Latimer, Chief Executive Officer

Telehealth Remote Clinical Trial

During the height of the COVID-19 pandemic, clinical trial sites appeared to face an existential threat as the industry discussed “siteless” decentralized trials. Two years later, conventional wisdom recognizes the importance of face-to-face interactions in clinical care and suggests that hybrid decentralized trials will grow faster [1] and be more prevalent [2] than fully decentralized ones. For sites, however, the rise of hybrid decentralized trials introduces another challenge: the adoption of new technologies. 


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader